| 摘要 |
<p>Stable therapeutic radionuclide compositions comprising, for example, ?186Re, 188Re and 131¿I stably bound to a proteinaceous targeting moiety and suitable for human in vivo administration are disclosed. Stabilizing agents preferably comprise antioxidants and challenging agents, and combination of HSA with an antioxidant and/or challenging agent provides enhanced long term stability. Ascorbic acid is an especially preferred stabilizing agent, which provides stability of therapeutic radionuclide compositions at levels of at least about 90 % for several hours up to several days.</p> |
